Intercell
| Company type | Public company |
|---|---|
| Industry | Biotechnology |
| Founded | 1998 |
| Headquarters | , |
| Products | Vaccination technology |
Intercell AG is a biotechnology company based in Vienna which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.[1] It employs 400 people in Austria, Scotland and the United States.
It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell acquired Iomai, a developer of needle-free vaccination technology, now operated as Intercell USA.[2]
Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.
The most important projects of Intercell are:
- Vaccine against Japanese encephalitis (aproved in Europe, America and Australia)[3] [4] [5]
- Therapeutic vaccine against hepatitis C (in clinical phase II)[6]
- Antigen identification program and adjuvant technologies.
- Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services, in clinical phase II)
References
- ^ "Research Institute of Molecular Pathology (IMP) - About the IMP > History". Research Institute of Molecular Pathology. Retrieved 2009-07-25.
- ^
"Austrian vaccine maker Intercell buys Iomai". Reuters. Retrieved 2008-08-15.
{{cite web}}: Unknown parameter|pubdate=ignored (help) - ^
"Intercell's Japanese Encephalitis Vaccine FDA aproval". Medical News Today. Retrieved 2009-03-31.
{{cite web}}: Unknown parameter|pubdate=ignored (help) - ^
"Intercell's Japanese Encephalitis Vaccine EMEA aproval for Europe". Intercell. Retrieved 2009-04-02.
{{cite web}}: Unknown parameter|pubdate=ignored (help) - ^
"Intercell's Japanese Encephalitis Vaccine Australian TGA aproval". Intercell. Retrieved 2009-01-23.
{{cite web}}: Unknown parameter|pubdate=ignored (help) - ^
"Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. Retrieved 2008-08-15.
{{cite web}}: Unknown parameter|pubdate=ignored (help)
External links
 | This Austria-related article is a stub. You can help Wikipedia by expanding it. |